Review
Chemistry, Medicinal
Itzel Jatziri Contreras-Garcia, Noemi Cardenas-Rodriguez, Antonio Romo-Mancillas, Cindy Bandala, Sergio R. Zamudio, Saul Gomez-Manzo, Beatriz Hernandez-Ochoa, Julieta Griselda Mendoza-Torreblanca, Luz Adriana Pichardo-Macias
Summary: This study provides a comprehensive review of levetiracetam, discussing its clinical uses, structural properties, therapeutic targets, and various molecular, genetic, and systemic action mechanisms, highlighting its potential as a candidate for drug repurposing.
Article
Clinical Neurology
Mohammed Abou Kaoud, Ran Nissan, Amitai Segev, Avi Sabbag, David Orion, Elad Maor
Summary: There is a strong signal of interaction between levetiracetam and direct oral anticoagulants (DOACs), suggesting the need for drug monitoring strategy.
Article
Clinical Neurology
Una Avdic, Matilda Ahl, My Andersson, Christine T. Ekdahl
Summary: This study found that treatment of fNCSE rats reduced brain pathology within the epileptic focus, but did not affect the persistence of epileptic seizures or behavioral differences.
FRONTIERS IN NEUROLOGY
(2021)
Article
Clinical Neurology
Meike Schelhaas, Ilse Wegner, Mireille Edens, Elisabeth Wammes-Van der Heijden, Daniel Touw, Peter Ter Horst
Summary: This study found that the concentration/dose ratio of levetiracetam decreases during pregnancy, but there is still a new target concentration range that is relatively safe. For patients who have had seizures within one year before pregnancy, the decrease in levetiracetam concentration is significantly correlated with seizure frequency deterioration.
Article
Neurosciences
Mazdak M. Bradberry, Edwin R. Chapman
Summary: SV2A is an essential synaptic vesicle protein that plays a role in regulating neurotransmitter release, but the exact mechanism is unclear. Knockout of SV2A in hippocampal neurons was found to reduce evoked glutamate release without affecting presynaptic Ca2+ entry, indicating that SV2A increases the likelihood of synaptic vesicle fusion triggered by Ca2+.
JOURNAL OF PHYSIOLOGY-LONDON
(2022)
Article
Chemistry, Medicinal
Changhee Ha, Hyun-Seung Lee, Eun Yeon Joo, Young-Min Shon, Seung Bong Hong, Dae-Won Seo, Soo-Youn Lee
Summary: The study investigated the therapeutic drug monitoring of Levetiracetam in Korean epilepsy patients, revealing a large inter-individual difference in its pharmacokinetics and its susceptibility to EIAEDs. There was a strong correlation between weight-adjusted Levetiracetam dosage and concentrations.
Article
Pharmacology & Pharmacy
Ludmila A. Kasatkina, Vitaliy P. Gumenyuk, Olha O. Lisakovska, Irene O. Trikash
Summary: Oligomeric forms of Aβ can compromise synaptic vesicle fusion machinery during neuroinflammation, while the antiepileptic agent levetiracetam can affect APP processing and Aβ generation within the hippocampus by targeting synaptic vesicle recycling and restricting overexcitation.
BIOCHEMICAL PHARMACOLOGY
(2022)
Article
Clinical Neurology
John Tyler Haller, Sophia Bonnin, John Radosevich
Summary: Rapid intravenous push administration of undiluted LEV is safe and well tolerated up to doses of 4500 mg, providing a means for rapid drug administration in neurological emergencies.
Article
Medicine, General & Internal
Rod W. Hunt, Helen G. Liley, Deepika Wagh, Rachel Schembri, Katherine J. Lee, Andrew D. Shearman, Samantha Francis-Pester, Koert DeWaal, Jeanie Y. L. Cheong, Monika Olischar, Nadia Badawi, Flora Y. Wong, David A. Osborn, Victor Samuel Rajadurai, Peter A. Dargaville, Bevan Headley, Ian Wright, Paul B. Colditz
Summary: This randomized clinical trial aimed to determine whether active management of electrographic and clinical seizures in encephalopathic term or near-term neonates improved survival free of severe disability at 2 years compared with only treating clinically detected seizures. The study found that treating electrographic and clinical seizures with currently used anticonvulsants did not significantly reduce the rate of death or disability at 2 years in a heterogeneous group of neonates with seizures. Additionally, there was evidence that cognitive outcomes were worse in the group where both types of seizures were actively managed.
Article
Medical Laboratory Technology
Dennis Klimpel, Anne Hagemann, Christian G. Bien, Bertin Dufaux, Theodor W. May, Christian Brandt
Summary: This study aimed to determine conversion factors for the estimation of AED serum concentrations from capillary blood concentrations. Results showed a linear relationship between serum and capillary blood concentrations for LTG, LEV, and LCM. Using a simple ratio approach and Passing-Bablok regression yielded the best results for all three AEDs.
THERAPEUTIC DRUG MONITORING
(2021)
Article
Pharmacology & Pharmacy
Junichi Yamamoto, Kaori Ikeda, Armel Stockis
Summary: This study characterized the bioavailability, safety, and tolerability of brivaracetam in healthy Japanese participants. The results showed that the AUC ratios of intravenous and oral administration were within the bioequivalence limits, but the C-max exceeded the limits. Therefore, no dose adjustment is needed when switching from oral to intravenous dosing, but further investigations are required to assess the safety and tolerability in patients with epilepsy.
Article
Oncology
Johannes Wach, Agi Gueresir, Motaz Hamed, Hartmut Vatter, Ulrich Herrlinger, Erdem Gueresir
Summary: This study investigated the impact of the antiepileptic drug levetiracetam on intraoperative fluorescence quality in glioblastoma surgery. The results showed that preoperative intake of levetiracetam significantly reduced intraoperative fluorescence. This finding suggests that careful evaluation and avoidance of prophylactic treatment with levetiracetam should be considered in glioblastoma patients.
Article
Pharmacology & Pharmacy
Armel Stockis, Jean-Marie Nicolas, Maria Laura Sargentini-Maier, Walter Krauwinkel
Summary: This study characterized the pharmacokinetics, metabolism, safety, and tolerability of BRV in healthy elderly participants aged 65-78 years. The results showed that BRV had similar pharmacokinetics and metabolism in older individuals compared to younger populations, and there were no clinically relevant changes or abnormalities. Rating scales indicated transiently increased sedation and decreased alertness. Dose reductions are not warranted in elderly individuals receiving oral BRV 200 mg twice daily.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT
(2023)
Article
Agriculture, Dairy & Animal Science
Sylvia Garcia-Belenguer, Laura Grasa, Olga Valero, Jorge Palacio, Isabel Luno, Belen Rosado
Summary: The study found differences in gut microbiota composition between epileptic dogs and control dogs, with drug-naive epileptic dogs showing significantly reduced abundance of GABA and SCFAs-producing bacteria, as well as bacteria associated with reduced risk for brain disease. Furthermore, the administration of antiepileptic drugs for a month did not alter the gut microbiota composition. These results may contribute to understanding canine idiopathic epilepsy and offer potential for exploring probiotic intervention as a therapeutic approach.
Article
Clinical Neurology
Kimford J. Meador, Morris J. Cohen, David W. Loring, Abigail G. Matthews, Carrie Brown, Chelsea P. Robalino, Angela K. Birnbaum, Paula E. Voinescu, Laura A. Kalayjian, Elizabeth E. Gerard, Evan R. Gedzelman, Julie Hanna, Jennifer Cavitt, Maria Sam, Jacqueline A. French, Sean Hwang, Alison M. Pack, Page B. Pennell, MONEAD Invest Grp
Summary: This study aimed to investigate the neurodevelopmental effects of fetal exposure to commonly used antiseizure medications, and found no difference in neurodevelopmental outcomes between children with fetal exposure to newer antiseizure medications compared with unexposed children.